Omega-3 and Cardiovascular Longevity: What REDUCE-IT and STRENGTH Actually Showed

Cardiovascular disease remains the leading cause of premature death and lost healthspan in adults over 40. Omega-3 fatty acids — primarily EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — have been studied as cardiovascular interventions for decades. The story looked settled in the 1990s. It got complicated again in the 2010s. And then two major trials published within two years of each other sent contradictory signals that experts are still debating.

Understanding those contradictions matters if you are trying to build a longevity supplement stack grounded in evidence rather than marketing. The short version: not all omega-3 supplements are the same compound, not all studies test the same population, and the mechanism driving the cardiovascular benefit in the winning trial may not be the one most people assume.

This is a deep-dive for readers who already understand the basics of cardiometabolic health and want to make a more informed decision about whether high-dose EPA, standard fish oil, or no omega-3 supplementation fits their personal risk profile and protocol. If you are earlier in your longevity learning curve, start with our overview of the best-evidence supplement categories before returning here.

REDUCE-IT (Reduction of Cardiovascular Events with Icosapentaenoic Acid-Intervention Trial) was published in the New England Journal of Medicine in 2018. It enrolled 8,179 adults who had either established cardiovascular disease or diabetes plus at least one additional risk factor. All participants were already on statin therapy and had fasting triglycerides between 135 and 499 mg/dL. They were randomized to 4 grams per day of icosapentaenoic acid ethyl ester — a highly purified EPA-only formulation — or a mineral oil placebo.

The result was striking: the EPA group experienced a 25% relative risk reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina. Cardiovascular death alone fell by 20%. These are large effect sizes for a supplement in a well-controlled trial. The study made purified EPA an approved drug in the United States under the brand name Vascepa for adults with elevated triglycerides already on statins.

The triglyceride reduction was meaningful but not large enough to explain the cardiovascular benefit on its own. EPA lowered triglycerides by roughly 19% versus placebo. Researchers proposed additional mechanisms including anti-inflammatory effects, membrane stabilization, reduced platelet aggregation, and plaque stabilization — but the exact driver remains debated. What is not debated is that the trial showed a real cardiovascular benefit in a high-risk population taking a specific purified EPA formulation.

STRENGTH (Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia) was published in JAMA in 2020. It enrolled a similar high-risk population with elevated triglycerides and cardiovascular risk, also on statin therapy. The intervention was 4 grams per day of a combined EPA plus DHA formulation — specifically Epanova, a free fatty acid omega-3 — versus corn oil placebo.

The trial was stopped early for futility. There was no cardiovascular benefit. The EPA plus DHA arm showed no significant reduction in major adverse cardiovascular events compared to the corn oil control group. In an almost identical population to REDUCE-IT, omega-3 supplementation appeared to do nothing.

The result shocked researchers and generated immediate debate about what differed between the two trials. The most discussed explanations include the different omega-3 formulations (EPA-only versus EPA plus DHA), the different placebo choices (mineral oil versus corn oil), possible differences in DHA's effect on LDL-C, and potential interactions between EPA and DHA that reduce EPA's individual benefit. None of these explanations is settled. The trials together created one of the most scrutinized disagreements in recent cardiometabolic medicine.

One of the most pointed criticisms of REDUCE-IT centers on its use of mineral oil as the placebo. Critics argued that mineral oil is not a truly inert comparator — it may raise LDL-C, hsCRP, and other inflammatory markers, making the EPA group look better by contrast rather than reflecting a genuine cardiovascular benefit from EPA itself. Several biomarker analyses from the trial appeared to support this concern.

REDUCE-IT investigators have pushed back, arguing that even under the most conservative interpretation of the placebo effect, the cardiovascular benefit remains clinically meaningful and consistent across pre-specified subgroups. Independent analyses have tried to model what the effect size would look like with an ideal placebo, and estimates range from 'somewhat smaller but still real' to 'substantially inflated.'

For practical decision-making, this controversy matters because it complicates how much confidence to place in the magnitude of the REDUCE-IT benefit. If you are a clinician deciding whether to prescribe Vascepa to a high-risk patient, you are weighing a 25% relative risk reduction that might really be a 12-18% risk reduction after accounting for placebo choice. That is still clinically significant. If you are a longevity-focused adult with normal triglycerides and no established CVD, the direct applicability is already limited — and the placebo question makes it harder to extrapolate.

Most fish oil supplements sold in pharmacies and supplement stores contain a mixture of EPA and DHA — typically in a roughly 1:1 to 1.5:1 EPA:DHA ratio. Standard 1-gram fish oil capsules often deliver 300-600 mg of combined omega-3s at a dose far below what was used in either major trial. REDUCE-IT used 4 grams of pure EPA. STRENGTH used 4 grams of EPA plus DHA combined.

The biological differences between EPA and DHA are real. DHA is a major structural component of neural cell membranes and is critical for brain development and cognitive maintenance. EPA is more directly involved in the eicosanoid signaling cascade — affecting inflammation, platelet function, and vascular tone. When you take both together, they compete for the same metabolic pathways. Some researchers believe DHA reduces the triglyceride-lowering and pleiotropic cardiovascular benefits of EPA, which might partially explain why the combined formulation in STRENGTH failed.

For longevity purposes this creates a genuine fork in the road. If your primary interest is brain health and cognitive aging, the evidence favors adequate DHA. If your primary interest is cardiometabolic risk reduction in the context of elevated triglycerides and statin use, the evidence for EPA-only at therapeutic doses is stronger. Most off-the-shelf fish oil sits in a no-man's land — low dose, mixed formulation, minimal evidence of cardiovascular benefit at typical retail dosing.

Beyond REDUCE-IT and STRENGTH, the omega-3 cardiovascular evidence base includes several other relevant trials. VITAL (Vitamin D and Omega-3 Trial) enrolled over 25,000 US adults and used 1 gram per day of combined omega-3 versus placebo. At that dose, there was no significant reduction in the primary composite cardiovascular endpoint — but there was a pre-specified finding of reduced heart attack risk in participants with low dietary fish intake, and a significant reduction in total cardiovascular events in that subgroup.

ASCEND (A Study of Cardiovascular Events in Diabetes) also used 1 gram per day and showed a modest but significant reduction in serious vascular events in people with diabetes, though the benefit was partly offset by a small increase in bleeding. ORIGIN (Outcome Reduction with an Initial Glargine Intervention), testing 1 gram of omega-3 in people with dysglycemia, showed no benefit.

The pattern across these trials suggests dose matters, population matters, and baseline dietary fish intake may determine who responds. People who already eat two or more fatty fish servings per week may receive little additional benefit from low-dose supplementation. People with very low dietary omega-3 intake, elevated triglycerides, and existing cardiovascular risk on statin therapy represent the population where the evidence is strongest — particularly for high-dose, purified EPA.

Translating this evidence into a personal longevity protocol requires matching your situation to the populations in the trials. The following framework is useful for most adults without established CVD: - **Step 1 — Assess your baseline dietary intake.** Do you eat two or more servings of fatty fish (salmon, sardines, mackerel, herring) per week? If yes, the incremental value of supplementation is lower. If no, your omega-3 status is likely suboptimal. - **Step 2 — Check your triglycerides.** The most compelling evidence for high-dose EPA involves people with triglycerides above 135 mg/dL on statin therapy. If your triglycerides are below 100, you are not in the primary REDUCE-IT population. - **Step 3 — Consider your cardiometabolic risk profile.** Standard-dose combined omega-3 (1-2 grams combined EPA+DHA daily) has a reasonable safety profile and may support inflammatory markers, joint health, and DHA status for brain maintenance even without a proven large cardiovascular outcome benefit. That is a different decision from expecting a 25% reduction in MACE. - **Step 4 — Consider EPA-only if clinically warranted.** If your cardiovascular risk is elevated, your triglycerides are high, and you are on statin therapy, discuss Vascepa or a high-purity EPA-only supplement with your physician. This is a prescription-grade decision, not a casual stack add-on.

There is also a practical case for standard-dose fish oil in a longevity protocol even without REDUCE-IT-level evidence. Omega-3 adequacy supports EPA and DHA status for multiple organ systems. The dose to maintain adequacy is lower than the dose used in clinical trials. A reasonable starting point for most adults without established CVD is 1-2 grams of combined EPA+DHA daily from a high-quality, oxidation-tested formulation. See our omega-3 supplement guide for quality selection criteria.

One underappreciated variable in omega-3 supplementation is oxidation. Fish oil is highly susceptible to lipid peroxidation — rancidity — both in the bottle and after ingestion. Oxidized omega-3 may actually promote rather than reduce cardiovascular inflammation. Studies testing retail fish oil products have found that a significant proportion of commercially available capsules exceed acceptable oxidation thresholds even before expiration.

Markers to assess include TOTOX (total oxidation) score, peroxide value, and anisidine value. Brands that publish these numbers from third-party testing — International Fish Oil Standards (IFOS), NSF, or similar — are meaningfully more trustworthy than those that don't. Molecular distillation and nitrogen flushing during manufacturing reduce oxidation risk. Soft gels with no fishy smell when cut open are a reasonable freshness proxy but not a guarantee.

For longevity-focused buyers, fish oil is one of the supplement categories where quality differentiation is most consequential. A cheaper oxidized product may be worse than no product. For detailed product comparisons including IFOS certification status and EPA:DHA ratios, see our ranked omega-3 buyer's guide.

**Does fish oil extend lifespan?** No study has shown a direct lifespan extension from omega-3 supplementation in humans. The evidence is for cardiometabolic risk reduction in specific high-risk populations at therapeutic doses. Extrapolating to general lifespan extension in healthy adults goes beyond what the trials support.

**Should I take EPA-only or EPA+DHA?** Depends on your goal. For cognitive aging and DHA status: combined supplementation or DHA-focused products make sense. For cardiometabolic risk reduction in a high-risk population on statins with elevated triglycerides: EPA-only at 4g/day is what the evidence supports, and that is a clinical decision. For general longevity maintenance: quality combined omega-3 at 1-2g/day is a reasonable middle ground.

**How do I know if my fish oil is fresh?** Bite or cut a capsule and smell it. Neutral or very mildly fishy is acceptable. Strongly rancid or paint-like smell is a red flag. Brands with IFOS or NSF Certified for Sport certification are preferred. Store in the fridge or freezer once opened.

**Is krill oil better?** Krill oil is marketed as more bioavailable due to its phospholipid form. Some research supports better DHA incorporation into red blood cells. However, krill oil products typically deliver far less EPA and DHA per capsule and at a higher cost per milligram. For therapeutic dosing, fish oil or fish oil ethyl esters remain more practical. For low-dose maintenance, krill oil is a defensible alternative with better palatability for some users.

**What about plant-based omega-3 (ALA)?** Alpha-linolenic acid from flaxseed, chia, and hemp converts to EPA and DHA at very low efficiency in humans — roughly 5-10% to EPA, less than 0.5% to DHA. Plant-based omega-3 cannot substitute for direct EPA/DHA supplementation for cardiovascular or cognitive purposes.

The REDUCE-IT and STRENGTH trials are a case study in why single trials, even large ones, require context. The signal from REDUCE-IT is real: purified high-dose EPA reduces cardiovascular events in a well-defined high-risk population already on statin therapy. The signal from STRENGTH is equally real: a combined EPA+DHA formulation at the same dose in a similar population showed no benefit. The gap between them is still being explained.

For most longevity-focused adults without established CVD, the actionable takeaway is: optimize dietary fish intake first, choose a high-quality, low-oxidation combined omega-3 supplement at 1-2 grams EPA+DHA daily if dietary intake is low, and reserve the EPA-only high-dose conversation for people with documented cardiovascular risk, elevated triglycerides, and a physician managing their statin therapy.

Omega-3 at appropriate doses is a low-risk, moderate-benefit intervention. It does not replace the cardiovascular protection offered by blood-pressure control, strength training, aerobic fitness, sleep quality, and reducing ApoB. It fits inside a well-constructed protocol rather than anchoring it. For related reading, see our VO2 max training guide, the berberine vs metformin evidence comparison, and our biomarker tracking guide for heart health.